Modern possibilities of antiepileptic therapy at the start of treatment of focal epilepsy
https://doi.org/10.17749/2077-8333/epi.par.con.2021.083
Abstract
The report presents data on the evaluation of efficacy and tolerability, as well as the dynamics of epileptiform activity index in adolescents and adults with newly diagnosed focal epilepsy during lacosamide therapy.
About the Author
P. N. Vlasov
Yevdokimov Moscow State University of Medicine and Dentistry
Russian Federation
Russian Federation
Pavel N. Vlasov – Dr. Med. Sc., Professor, Chair of Nervous Diseases
10 bld. 2 Vuchetich Str., Moscow 127206
References
1. Glauser T., Ben-Menachem E., Bourgeois B. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013; 54 (3): 551–63. https://doi.org/10.1111/epi.12074.
2. Lebedeva A.V., Burd S.G., Belyaev O.V., et al. Russian experience of lacosamide (vimpat) usage in treatment of uncontrolled focal epilepsy. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2016; 116 (9-2): 74–81 (in Russ.). https://doi.org/10.17116/jnevro20161169274-81.
3. Mukhin K.Yu., Tysyachina M.D., Glukhova L.Yu., Freidkova H.V. A clinical case of using lacosamide (vimpat) in the treatment of drug-resistant symptomatic epilepsy. Russian Journal of Child Neurology. 2011; 6 (2): 38–42 (in Russ.).
4. Mironov M.B., Mukhin K.Yu., Pylaeva O.A. Efficacy of vimpat (lacosamide) in the treatment of drug-resistant cryptogenic focal epilepsy with focal automotor and secondarily generalized seizures (a clinical case). Russian Journal of Child Neurology. 2012; 7 (2): 3–12 (in Russ.).
5. Rudakova I.G., Vlasov P.N., Lipatova L.V., Voronkova K.V. Lacosamide (vimpat). Prospects for clinical application. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2017; 117 (9): 147–52. https://doi.org/10.17116/jnevro201711791147-152.
6. Iakovleva Iu.A., Yanaeva A.N., Spikina A.A., Rukavitsyna E.L. Lacosamide in treatment of patients with focal epilepsy and comorbid mental disorders. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2018; 118 (10-2): 98–104. https://doi.org/10.17116/jnevro201811810298.
7. Vlasov P.N., Kamelkova E.G., Drozzhina F.R. Efficacy and tolerance of intravenous lacosamide in urgent neurological situations. Neurology, Neuropsychiatry, Psychosomatics. 2012; 4 (1S): 60–3 (in Russ.). https://doi.org/10.14412/2074-2711-2012-2501.
8. Litvinova S.A., Avakyan G.G., Nerobkova L.N., et al. Effect of lacosamide on epileptiform activity and structure-function relations in the brain of rats with chronic focal epilepsy. Epilepsia i paroksizmalʹnye sostoania / Epilepsy and Paroxysmal Conditions. 2019; 11 (1): 37–45 (in Russ.). https://doi.org/10.17749/2077-8333.2019.11.1.37-45.
9. Karlov V.A., Kozhokaru A.B., Vlasov P.N., et al. Efficacy assessment of levetiracetam monotherapy in newly-diagnosed epilepsy in adults using epileptiform activity index. Epilepsia i paroksizmalʹnye sostoania / Epilepsy and Paroxysmal Conditions. 2020; 12 (2): 93–104 (in Russ.). https://doi.org/10.17749/2077-8333/epi.par.con.2020.024.
10. Karlov V.A., Kozhokaru A.B., Vlasov P.N., et al. Dynamics of epileptiform activity, efficacy and tolerability of valproic acid in adults and adolescents with newly-diagnosed epilepsy. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2020; 120 (7): 35–43. https://doi.org/10.17116/jnevro202012007135.
11. Karlov V.A., Vlasov P.N., Kozhokaru A.B., et al. The efficiency and tolerability of lacosamide therapy in adolescents and adults with new-onset focal epilepsy in terms of the epileptiform activity index. Neurology, Neuropsychiatry, Psychosomatics. 2020; 12 (3): 56–62. https://doi.org/10.14412/2074-2711-2020-3-56-62.
Review
For citations:
Vlasov P.N. Modern possibilities of antiepileptic therapy at the start of treatment of focal epilepsy. Epilepsy and paroxysmal conditions. 2021;13(1S):74-78. (In Russ.) https://doi.org/10.17749/2077-8333/epi.par.con.2021.083
Views:
451
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 
